| Literature DB >> 14638974 |
M N Meriggioli1, E Ciafaloni, K A Al-Hayk, J Rowin, B Tucker-Lipscomb, J M Massey, D B Sanders.
Abstract
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14638974 DOI： 10.1212/01.wnl.0000094122.88929.0b
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910